Company Performance Metrics
Kindling Bio develops child-first gene therapies to treat childhood cancers. The company focuses on pediatric oncology, recognizing that childhood cancers are biologically distinct from adult cancers and often respond poorly to adult-designed treatments. Its approach centers on a gene therapy platform that uses the strengths of the child immune
system to recognize and eliminate tumors. Kindling Bio targets pediatric cancers as developmental diseases, working to make tumors visible to immune cells so they can be safely destroyed. The company collaborates with academic and research partners to advance precision therapies for children with hard-to-treat cancers. It positions its technology to address a broad range of childhood tumor types through immune-targeted interventions.
